Detalhe da pesquisa
1.
Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis.
Drug Metab Dispos
; 37(10): 2061-8, 2009 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-19581389
2.
Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism.
Eur J Clin Pharmacol
; 64(11): 1057-68, 2008 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-18607581
3.
Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients.
Eur J Clin Pharmacol
; 64(9): 871-6, 2008 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-18496682
4.
Subcutaneous infection with Pseudallescheria boydii in an immunocompromised patient.
Clin Rheumatol
; 26(6): 1023-4, 2007 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-16572287
5.
Genetic determinants of methotrexate treatment in rheumatoid arthritis patients: a study of polymorphisms in the adenosine pathway.
Ann Rheum Dis
; 69(5): 931-2, 2010 May.
Artigo
Inglês
| MEDLINE | ID: mdl-20413572
6.
Genetic variation in the SLC19A1 gene and methotrexate toxicity in rheumatoid arthritis patients.
Pharmacogenomics
; 13(14): 1583-94, 2012 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-23148635